Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anita Banerjee

Cardiovascular Disease Springfield, VA Medical Doctor

NPI 1073630273 CMS profile 2972

5514 Alma Ln, Ste 200, Springfield, VA 22151

Open in the dashboard

General payments

$8,992

320 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$40,791 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Anita Banerjee of Springfield, VA is reported in the CMS Open Payments database as having received $8,992 across 320 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $40,791 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,262 52
2024 General $1,274 49
2023 General $3,707 93
2022 General $1,414 68
2021 General $683 42
2020 General $314 10
2019 General $336 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anita Banerjee
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Anita Banerjee were reported at $1,262. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Anita Banerjee Cardiovascular Disease median Middle half National median
2019 $336 $450 $127–$1,392 $163
2020 $314 $242 $77–$751 $114
2021 $683 $335 $101–$1,037 $132
2022 $1,414 $395 $121–$1,211 $149
2023 $3,707 $443 $136–$1,283 $160
2024 $1,274 $450 $136–$1,323 $164
2025 $1,262 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,338 76 payments
  2. Bard Peripheral Vascular, Inc. $1,327 15 payments
  3. Medtronic, Inc. $1,326 20 payments
  4. Novartis Pharmaceuticals Corporation $678 36 payments
  5. Merck Sharp & Dohme Corporation $621 34 payments
  6. Boston Scientific Corporation $532 12 payments
  7. Pfizer Inc. $460 19 payments
  8. E.R. Squibb & Sons, L.L.C. $237 13 payments
  9. Medtronic Vascular, Inc. $220 5 payments
  10. Biotronik Inc. $199 4 payments
  11. Other $2,054 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,763 309 payments
  2. Travel and Lodging $2,218 10 payments
  3. Education $11 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $1,338 76 payments
  2. Venclose Maven Catheter $1,331 16 payments
  3. VENASEAL $1,058 7 payments
  4. VERQUVO $725 40 payments
  5. LEQVIO $528 29 payments
  6. ELIQUIS $374 15 payments
  7. Varithena Administration Pack $345 4 payments
  8. ENTRESTO $236 12 payments
  9. Coala Heart Monitor $181 6 payments
  10. NEXLETOL $170 10 payments
  11. Other $3,403 142 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,038

Median for Cardiology: 2,533

Drug cost

$446,633

Median for Cardiology: $485,213

Branded share of claims

22.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 222 $273,983
Entresto Sacubitril/Valsartan Brand 60 $77,299
Xarelto Rivaroxaban Brand 38 $52,267
Ozempic Semaglutide Brand 12 $11,249
Vascepa Icosapent Ethyl Brand 20 $9,200
Flecainide Acetate Generic 48 $3,523
Metoprolol Succinate Generic 173 $3,363
Carvedilol Generic 239 $1,805
Atorvastatin Calcium Generic 145 $1,578
Bumetanide Generic 31 $1,540

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$774,850

Of which drugs: $955

Medicare patients

969

Average age 76

Services billed

5,655

562 women, 407 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 42%
Atrial fibrillation 41%
Diabetes 34%
Heart failure 30%
Chronic kidney disease 29%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 34 136 $955

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $104
$104 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $95
$95 — —
ELIQUIS
  • PFIZER INC. $41
  • E.R. Squibb & Sons, L.L.C. $20
$61 222 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $51
$51 — —
Ozempic
  • Novo Nordisk Inc $45
$45 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record